Diffuse alveolar haemorrhage

Singapore General Hospital Proceedings

Volumn 17, Issue 2, 2008, Pages 94-105

  Tze Yi, Steve Yang ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Diffuse lung infiltrates; Haemoptysis; Pulmonary vasculitis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FIBRINOLYTIC AGENT; HEPARIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; OXYGEN; PENICILLAMINE; PHENYTOIN; PREDNISOLONE; PROPYLTHIOURACIL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RETINOIC ACID; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; TOXIN; UNINDEXED DRUG; WARFARIN;

ADJUVANT THERAPY; ANCA ASSOCIATED VASCULITIS; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CAPILLARITIS; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; FIBEROPTIC BRONCHOSCOPY; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOSIDEROSIS; HUMAN; HYPOXEMIA; INFECTION; INHALATION; LABORATORY TEST; LUNG ALVEOLUS; LUNG BIOPSY; LUNG HEMORRHAGE; LUNG INFILTRATE; LUNG LAVAGE; MAINTENANCE THERAPY; MEDICAL ASSESSMENT; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; MORTALITY; OXYGEN THERAPY; PATHOGENESIS; PLASMAPHERESIS; PULMONARY VASCULITIS; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; THORAX RADIOGRAPHY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

EID: 51349135442     PISSN: 02183048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (150)

1. Pesci A, Pavone L, Buzio C, Manganelli P. Respiratory system involvement in ANCA-associated systemic vasculitides. Sarc Vasc Diffuse Lung Dis 2005; S22:S48
2. Fauci AS, Haynes BF, Katz P. The spectrum of vasculitis. Ann Intern Med 1978; 89:660-76
3. Abud-Mendoa C, Diaz-Jouanen E, Alarcon-Segovia D. Fatal pulmonary hemorrhage in systemic lupus erythematosus: Occurrence without hemoptysis. J Rheumatol 1985; 12:58-61.
4. Leatherman JW, Davies SF, Hoidal JR. Alveolar hemorrhage syndromes: Diffuse microvascular lung hemorrhage in immune and idiopathic disorders. Medicine (Baltimore) 1984; 63:343-61.
5. Mintz G, Galindo LF, Fernandez-Diez J, Jimenez FJ, Robles-Saa Vedra E, Enriquez-Casillias RD. Acute massive pulmonary hemorrhage in systemic lupus erythematosus. J Rheumatol 1978; 5:39-50.
6. Green RJ, Ruoss SJ, Kraft SA, Berry GJ, Raffin TA. Pulmonary Capillaritis and Alveolar Hemorrhage: Update on Diagnosis and Management. Chest 1996; 110:1305-16.
7. Anantham D, Chan KP, Chuah KL, Vathsala A, Eng P. Pulmonary capillaritis in IgA nephropathy. South Med J 2007; 100:605-7.
8. Collard HE, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med, 2004; 25:583-592.
9. Greening AP, Hughs JMB. Serial estimation of carbon monoxide diffusing capacity in intra-pulmonary hemorrhage. Clin Sci 1981; 60:507-512.
10. Ewan PW, Jones HA, Rhodes CG, Hughes JM. Detection of intrapulmonary hemorrhage with carbon monoxide uptake: application in Goodpasture's syndrome. N Engl J Med 1976; 295:1391-6.
11. Drew WL, Finley TN, Golde DW. Diagnostic lavage and occult pulmonary hemorrhage in thrombocytopenic immunocompromised patients. Am Rev Respir Dis 1977; 116:343-61.
12. Kahn FW, Jones JM, England DM. Diagnosis of pulmonary haemorrhage in the immunocompromised host. Am Rev Respir Dis 1987; 136:155-60.
13. Colby TV, Fukuoka J, Ewaskow SP, Helmers R, Leslie KO. Pathologic approach to pulmonary hemorrhage. Ann Diagn Pathol 2001; 5:309-19.
14. Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990; 14:1112-25.
15. Choi AM, Elbon CL, Bruce SA, Basset DJ. Messenger RNA levels of lung extracellular matrix proteins during ozone exposure. Lung 1994; 172:15-20.
16. Cohen-Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149:2461-65.
17. Savige J, Gillis D, Benson E, Davis D, Esnault V, Falk RJ et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111:507-13.
18. Mandl LA, Solomon DH, Smith EL, Lew RA, Katz JN, Shmerling RH. Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 2002; 162:1509-14.
19. Boomars KA, Wagenaar SS, Mulder PG, van Velzen-Blad H, van den Bosch JM. Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 1995; 50:1087-92.
20. Mulder AH, Horst G, van Leeuwen MA, Limburg PC, Kallenberg CG. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis: characterization and clinical correlations. Arthritis Rheum 1993; 36:1054-60.
21. Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus: prevalence, specificities, and clinical significance. Arthritis Rheum 1995; 38:633-37.
22. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 166:488-98.
23. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM. Wegener's granulomatosis: a series of 265 British cases seen between 1975 and 1985: a report by a sub-committee of the British Thoracic Society Research Committee. QJ Med 1992; 83:427-38.
24. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Rauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody raters in patients with Wegener's granulomatosis. Adv Exp Med Biol 1993; 336:411-14.
25. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Jermans J, Kallenberg CG et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43:2025-33.
26. Noille B, Specks U, Ludemann J, Rohrbach MS, DeRemee RA Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's Granulomatosis. Ann Intern Med 1989; 111:28-40.
27. Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Am J Surg Pathol 1991; 15:315-33.
28. Lie JT. Illustrated histopathologic classification criteria for selected vasculitic syndromes. Arthritis Rheum 1990; 33:1074-87.
29. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004; 51:83-91.
30. Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant 2005; 20:96-104.
31. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: a comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36:1290-97.
32. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666-73.
33. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93:433-9.
34. Regan MJ, Hellmann DB, Stone JH. Treatment of Wegener's granulomatosis. Rheum Dis Clic North Am 2001; 27:863-86.
35. Ahmed SH, Aziz T, Cochran J, Highland K. Use of extracorporeal membrane oxygenation in a patient with diffuse alveolar hemorrhage. Chest 2004; 126:305-9.
36. Khan SA, Subla MR, Behl D, Specks U, Afessa B. Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest 2007; 131:972-76.
37. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P et al. Microscopic polyangiitis. Arthritis Rheum 1999; 42:421-30.
38. Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Semin Respir Crit Care Med 1998; 19:27-45.
39. Akikusa B, Sato T, Ogawa M, Ueda S, Kondo Y. Necrotizing alveolar capillaritis in autopsy cases of microscopic polyangiitis: incidence, histopathogenesis and relationship with systemic vasculitis. Arch Pathol Lab Med 1997; 121:144-49.
40. Doebbeling BN, Bonsib SM, Walher WP. Pulmonaryrenal syndrome with "triad" involvement due to small vessel vasculitis. J Rheumatol 1990; 17:1087-90.
41. Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonaryrenal vasculitis in elderly patients. Mayo Clin Proc 1990; 65:847-56.
42. Guillevin L, Guittard T, Bletry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 1987; 165:165-72.
43. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine 1999; 78:26-37.
44. Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984; 63:65-81.
45. Guillevin L, Hong Du LT, Godeau P, Jais P, Wechsler B. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol 1988; 27:258-64.
46. Morgan JM, Raposo L, Gibson DG. Cardiac involvement in Churg-Strauss syndrome shown by electrocardiography. Br Heart J 1989; 62:462-66.
47. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284-90.
48. Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 2000; 39:585-95.
49. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42:1149-53.
50. Henke D, Falk RJ, Gabriel DA. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 2004; 140:493-4.
51. Lembrecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:1303-7.
52. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-32.
53. Klienert J, Lorenz M, Kostler W, Horl W, Sunder-Plassmann G, Soleiman A. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr 2004; 116:334-8.
54. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206:496-501.
55. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J et al. Prospective study of TNFaplha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-21.
56. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65:1440-8.
57. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-8.
58. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:830-1.
59. Bosch X, Font J, Mirapeix E, Revert L, Ingelmo M, Urbano-Marquez A. Antimyeloperoxidase autoantibody-associated necrotizing alveolar capillaritis. Am Rev Respir Dis 1992; 146(5 Pt 1):1326-9.
60. Jennings CA, King Jr TE, Tuder R, Cherniack RM, Schwarz MI. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med 1997; 155:1101-9.
61. Nicolls MR, Terada LS, Tuder RM, Prindiville SA, Schwarz MI. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998; 158:1302-5.
62. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus: Long-term follow-up of an inception cohort. Arthritis Rheum 1995 38; 1492-99.
63. Abud-Mendoza C, Diaz-Jouanen E, Alarcon-Segovia D. Fatal pulmonary hemorrhage in systemic lupus erythematosus. Occurrence without hemoptysis. J Rheumatol 1985; 12:558-61.
64. Leatherman JW, Favies SF, Hoidal JR. Alveolar hemorrhage syndromes: Diffuse microvascular lung hemorrhage in immune and idiopathic disorders. Medicine (Baltimore) 1984; 63:343-61.
65. Mintz G, Galindo LF, Fernandez-Diez J, Jimenez FJ, Robles Saavedra E, Enriquez-Casillas RD. Acute massive pulmonary hemorrhage in systemic lupus erythematosus. J Rheumatol 1978; 5:39-50.
66. Byrd RB, Trunk G. Systemic lupus erythematosus presenting as pulmonary hemosiderosis. Chest 1973; 64:128-29.
67. Carette S, Macher AM, Nussbaum A, Plotz PH. Severe, acute pulmonary disease in patients with systemic lupus erythematosus: Ten years experience at the National Institutes of Health. Semin Arthritis Rheum 1984; 14:52-9.
68. Finely TN, Aronow A, Cosentino AM, Golde DW. Occult pulmonary hemorrhage in anticoagulated patients. Am Rev Respir Dis 1975; 142:23-9.
69. Robboy SJ, Minna JD, Coleman RW, Birudorf NI, Lopas H. Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: Analysis of ten cases. Chest 1973; 63:718-21.
70. Gould DB, Soriano RZ. Acute alveolar hemorrhage in lupus erythematosus. Ann Intern Med 1975; 83:836-37.
71. Elliot ML, Kuhn C. Idiopathic pulmonary hemosiderosis: Ultrastructural abnormalities in the capillary walls. Am Rev Respir Dis 1970; 102:895-904.
72. Myers JL, Katzenstein ALA. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol 1986; 85:552-56.
73. Marino CT, Pertschik LP. Pulmonary hemorrhage in systemic lupus erythematosus. Arch Intern Med 1981; 141:201-3.
74. Onomura K, Nakata H, Tanaka Y, Tsuda T. Pulmonary hemorrhage in patients with systemic lupus erythematosus. J Thorac Imaging 1991; 6:57-61.
75. Eagen JW, Memoli VA, Roberts JL, Matthey GR, Schwartz MM, Lewis EJ. Pulmonary hemorrhage in systemic lupus erythematosus. Medicine (Baltimore) 1978; 57:545-60.
76. Schwab EP, Schumacher HR, Freundlich B, Callegari PE. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum 1993; 23:8-15.
77. Kelly PT, Haponik EF. Goodpasture syndrome: Molecular and clinical advances. Medicine (Baltimore) 1994; 73:171-85.
78. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326:1373-79.
79. Peters DK, Rees AJ, Lockwood CM, Pusey CD. Treatment and prognosis of antibasement membrane antibody mediated nephritis. Transplant Proc 1982; 14:513-21.
80. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA et al Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80:355-77.
81. Gertner E. Diffuse alveolar hemorrhage in the antiphospholipid syndrome: spectrum of disease and treatment. J Rheumatol 1999; 26:805-7.
82. Crausman RS, Achenbach GA, Pluss WT, O'Brien RF, Jennings CA. Pulmonary capillaritis and alveolar hemorrhage associated with the antiphospholipid antibody syndrome. J Rheumatol 1995; 22:554-6.
83. Schwarz MI, Sutarik JM, Nick JA, Leff JA, Emlen JW, Tuder RM. Am J Respir Crit Care Med 1995; 151:2037-40.
84. Horiki T, Fuyano G, Ishii M, Sasao T, Shibuya M, Yanagimachi N. Fatal alveolar hemorrhage in a patient with mixed connective tissue disease presenting polymyositis features. Intern Med 1998; 37:554-60.
85. Schwarz MI, Zamora MR, Hodges TN, Chan ED, Bowler RP,, Tuder RM. Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective disease. Chest 1998; 113:1609-15.
86. Griffin MT, Robb JD, Martin JR. Diffuse alveolar haemorrhage associated with progressive systemic sclerosis. Thorax 1990; 45:903-4.
87. Alvarez JL, Salazar Vallinas JM, Ortega Alberdi R, Munoz Sanz A, Turegano JM. Fernandez Alonso J. Pulmonary haemorrhage and focal necrotizing glomerulonephritis in a case of systemic sclerosis. Clin Rheumatol 1992; 11:116-9.
88. Vasquez-Del Mercado M, Mendoza-Topete A, Best-Aquilera CR, Garcia-De La Torre I. Diffuse alveolar hemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies. J Rheumatol 1996; 23:1821-83.
89. Derry CJ, Pickering M, Baker C, Pusey CD. Identification of the Goodpasture antigen, alpha 3(IV) NC1, and four other NC1 domains of type IV collagen, by amino-terminal sequence analysis of human glomerular basement membrane separated by two-dimensional electrophoresis. Exp Nephrol 1994; 2:249-56.
90. Hellmark T, Johansson C, Wieslander J. Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Kidney Int 1994; 46:823-29.
91. Hellmark T, Segelmark M, Unger C, Burkhardt H, Saus J, Wieslander J. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int. 1999; 55:936-44.
92. Lombard CM, Colby TV, Elliot CG. Surgical pathology of the lung in anti-basement membrane antibody associated with Goodpasture's syndrome. Hum Pathol 1989; 20:445-51.
93. Matthew TH, Hobbs JB, Kalowski S, Sutherland PW, Kincaid-Smith P. Goodpasture's syndrome: normal renal diagnostic findings. Ann Intern Med 1975; 82:215-8.
94. Beirne GJ, Octaviano GN, Kopp WL, Burns RO. Immunohistology of the lung in Goodpasture's syndrome. Ann Intern Med 1968; 69:1207-12.
95. Abboud RT, Chase WH, Balloon HS, Grzybowski S, Magil A. Goodpasture's syndrome: diagnosis by transbronchial lung biopsy. Ann Intern Med 1978; 89(5 Pt 1):635-8.
96. Herody M, Bobrie G, Gouarin C, Grunfeld JP, Noel LH. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol 1993; 40:249-55.
97. Jennings L, Roholt OA, Pressman D, Blau M, Andres GA, Brentjens JR. Experimental anti-alveolar basement membrane antibody-mediated pneumonitis.. The role of increased permeability of the alveolar capillary wall induced by oxygen. J Immunol 1981; 127:129-34.
98. Zimmerman CM, Varanasi VR, Hoff B. Goodpastures's syndrome with normal renal function. Am J Med 1979; 66:163-171.
99. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033-42.
100. Teague CA, Doak PB, Simpson IJ, Rainer SP, Herdson PB. Goodpasture's syndrome: an analysis of 29 cases. Kidney Int 1978; 13:492-504.
101. Rees AJ. Pulmonary injury caused by anti-basement membrane antibodies. Semin Respir Dis 1984; 5:264-72.
102. Maphaul JJ, Mullins JD. Glomerulonephritis mediated by antibody to glomerular basement membrane: Immunologic, clinical and histopathological characteristics. J Clin Invest 1976; 57:351-61.
103. Rosenblatt SG, Knight W, Bannayan GA, Wilson CB, Stein JH. Treatment of Goodpasture's syndrome with plasmapheresis. A case report and review of the literature. Am J Med 1979; 66:689-96.
104. Hind CR, Paraskevakou H, Lockwood CM, Evans DJ, Peters DK, Rees AJ. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1983; 1:263-65.
105. Morgan PG, Tuner-Warwick M. Pulmonary haemosiderosis and pulmonary haemorrhage. Br J Dis Chest 1981; 75:225-42.
106. Soergel K, Sommers SC. Idiopathic pulmonary hemosiderosis and related syndromes. Am J Med 1962; 32:499-511.
107. Beckerman RC, Taussig LM, Pinnas JL. Familial idiopathic pulmonary hemosiderosis. Am J Dis Child 1979; 133:609-11.
108. Thaell JF, Greipp PR, Stubbs SE, Siegal GP. Idiopathic pulmonary hemosiderosis: two cases in a family. Mayo Clin Proc 1978; 53:113-18.
109. Cassimos CD, Chryssanthopoulos C, Panagiotidou C. Epidemiologic observations in idiopathic pulmonary haemosiderosis. J Pediatr 1982; 698-702.
110. Choremis CB, Messaritakis JM, Karpouzas JG. Idiopathic pulmonary haemosiderosis. Lancet 1965; 10:499.
111. Marsaniotis N, Karpouzas J, Apostolopoulou E, Messaritakis J. Idiopathic pulmonary haemosiderosis in children. Arch Dis Child 1968; 43:307-9.
112. Cohen S. Idiopathic pulmonary hemosiderosis. Am J Med Sci 1999; 317:67-74.
113. Saeed MM, Woo MS, MacLaughlin EF, Margetis MF, Keens TG. Prognosis in pediatric idiopathic pulmonary haemosiderosis. Chest 1999; 116:721-25.
114. Chryssanthopoulos C, Cassimos C, Panagiotidou. Prognostic criteria in idiopathic pulmonary hemosiderosis in children. Eur J Pediatr 1983; 140:123-25.
115. Ali A, Milman N, Clausen PP. Idiopathic pulmonary haemosiderosis. Favourable effect of corticosteroids in two women aged 16 and 55 years. Eur Respir Topic 1998; 4:53-7.
116. Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166:641-5.
117. Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant 2000; 26:539-43.
118. Weisdorf DJ. Diffuse alveolar hemorrhage: an evolving problem? Leukemia 2003; 1049-50.
119. Jules-Elysee K, Stover DE, Yahalom J, White DA, Gulati SC. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis 1992; 136:485-91.
120. Robbins RA, Linder J, Stahl MG, Thompson AB III, Haire W, Kessinger A et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989; 87:511-18.
121. Huaringa AJ, Leyva FJ, Giralt SA, Blanco J, Singes-Costa J, Velarde H et al. Outcome of bone marrow transplantation patients requiring mechanical ventilation. Cri Care Med 2000; 28:1014-17.
122. Sisson JH, Thompson AB, Anderson JR, Robbins RA, Spurzem JR, Spence PR et al. Airway inflammation predicts diffuse alveolar hemorrhage during bone marrow transplantation in patients with Hodgkin disease. Am Rev Respir Dis 1992; 146:439-43.
123. Crilley P, Topolsky D, Styler MJ, Bernstein E, Resnick K, Mullaney R et al. Extramedullary toxicity of a conditioning regime containing busulphan, cyclophosmoamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplant 1995; 15:361-65.
124. Metcalf JP, Rennard SI, Reed EC, Haire WD, Sisson JH, Walter T et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation: University of Nebraska Medical Center Bone Marrow Transplant Group. Am J Med 1994; 96:327-34.
125. Witte RJ, Gurney JW, Robbins RA, Linder J, Rennard SI Arneson M et al. Diffuse pulmonary alveolar hemorrhage after bone marrow transplantation: radiographic findings in 39 patients. AJR Am J Roentgenol 1991; 157:461-64.
126. Wojno KJ, Vogelsang GB, Beschorner WE, Santos GW. Pulmonary hemorrhage as a cause of death in allogeneic bone marrow recipients with severe acute graft-versus-host disease. Transplantation 1994; 57:88-92.
127. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry MC et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128:1385-92.
128. Roychowdhury M, Pambuccian SE, Asian DL, Jessurun J, Rose AG, Manivel JC et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med 2005; 129:366-71.
129. Agusti C, Ramirez J, Picado C, Xaubet A, Carreras E, Ballester E, Torres A et al. Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation. A postmortem study. Am J Respir Crit Care Med 1995; 151:1006-10.
130. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2007: 13:1244-5.
131. Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166:1364-68.
132. Raptis A, Mavroudis D, Suffredini A, Molldrem J, Rhee FV, Childs R et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999; 24:879-883.
133. Chao NJ, Duncan SR, Long GD, Horning SJ, Blume KG. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Ann Intern Med 1991; 114:145-6.
134. Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003; 124:2400-3.
135. Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30:975-78.
136. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28:405-7.
137. Rees AJ, Lock wood CM, Peters DK. Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection. BMJ 1977; 2:723-76.
138. Katzenstein AL, Bloor C, Liebow AA. Diffuse alveolar damage: The role of oxygen, shock and relate factors. Am J Pathol 1976; 85:210-26.
139. Cooper JAD, White DA, Matthay RA. Drug induced pulmonary disease. Am Rev Respir Dis 1986; 133:321-40.
140. Drent M, Wessels S, Jacobs JA, Thijssen H. Association of diffuse alveolar haemorrhage with acquired vitamin K deficiency. Respiration (Herrlisheim) 2000; 67:697.
141. Kilaru PK, Schweiger MJ, Kozman HA, Weil TR. Diffuse alveolar hemorrhage after clopidogrel use. J Invasive Cardiol 2001; 13:535-57.
142. Gopalakrishnan D, Tioran T, Emanuel C, Clark VL. Diffuse pulmonary hemorrhage complicating thrombolytic therapy for acute myocardial infarction. Clin Cardiol 1997; 20:298-300.
143. Kalra S, Bell MR, Rihal CS. Alveolar hemorrhage as a complication of treatment with abciximab. Chest 2001; 120:126-31.
144. Dhillon SS, Singh D, Doe N, Qadri AM, Ricciardi S, Schwarz MI. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 1999; 116:1485-8.
145. Polman AJ, van der Weft TS, Tiebosch AT, Zijlstra JG. Early-onset phenytoin toxicity mimicking a renopulmonary syndrome. Eur Respir J 1998; 11:501-3.
146. Chang-Poon VY, Hwang WS, Wong A, Berry J, Klassen J, Poon MC. Pulmonary angiomatoid vascular changes in mitomycin C-associated hemolytic-uremic syndrome. Arch Pathol Lab Med 1985; 109:877-8.
147. Sternlieb I, Bennet B, Scheinberg IH. D-penicillamine induced Goodpasture's syndrome in Wilson's disease. Ann Intern Med 1975; 82:673-6.
148. Gavaghan TE, McNaught PJ, Ralston M, Hayes JM. Penicillamine-induced Goodpasture's syndrome: successful treatment of a fulminant case. Aust N Z J Med 1981; 11:261-
149. Matloff DS, Kaplan MM. D-penicillamine-induced Goodpasture's-like syndrome in primary biliary cirrhosis: successful treatment with plasmapheresis and immunosuppressives. Gastroenterology 1980; 78:1046-9.
150. Brown KK. Pulmonary vasculitis. Proc Am Thor Soc 2006; 3:48-57.